Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

Lauren A Quinn; Sunaya H Hirani; Thomas C Williams; Ian P Sinha

doi:10.1183/20734735.0110-2021

Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

Breathe (Sheff). 2021 Dec;17(4):210110. doi: 10.1183/20734735.0110-2021.

Authors

Lauren A Quinn¹, Sunaya H Hirani², Thomas C Williams^{3

4

5}, Ian P Sinha^{2

6

5}

Affiliations

¹ Queens University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK.
² Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
³ Dept of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK.
⁴ Department of Child Life and Health, University of Edinburgh, Edinburgh, UK.
⁵ Joint senior authors.
⁶ Division of Child Health, University of Liverpool, Liverpool, UK.

Abstract

It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants. https://bit.ly/3ikzwZD.

Publication types

Editorial
Comment